Clinical Study of Neoadjuvant Therapy With Apatinib and Paclitaxel in Local Advanced Triple-negative Breast Cancer

Exclusion Criteria

• •1. patients with pregnancy or lactation;
• •2. inflammatory breast cancer patients;
• •3. patients with several factors affecting medication (for example, inability to swallow, such as nausea, vomiting, chronic diarrhea, and bowel obstruction);
• •4. injury or pathologic fracture;
• •5. people with high blood pressure and antihypertensive drug treatment could not be reduced to within the normal range (systolic \>140 mmHg, diastolic pressure \>90 mmHg) ;
• •6. with ⅱ grade myocardial ischemia, poor control of arrhythmias or myocardial infarction (including QTc interval men ≥450 Ms, female ≥470 Ms);
• •7. according to NYHA standard ⅲ\~ⅳ -class heart insufficiency or heart ultrasound: LVEF(left ventricular ejection fraction) \<50%;
• •8. the past 6 months have gastrointestinal bleeding within history or definite gastrointestinal bleeding, such as: risk of bleeding oesophageal varicose ulcer lesions, fecal occult blood, local activities ≥ (++) Into groups; such as the fecal occult blood (+), requires endoscopy;
• •9. prior to participating in the study of 28 days abdominal fistula, perforation of the gastrointestinal tract and abdominal abscesses;
• •10. positive patients of urinary protein (urine protein 2+ or above, or 24 -hour urine protein \> 1.0g);
• •11. distant metastasis of patients with symptoms or are not controlled;
• •12. expected lifetime \< 3 months;
• •13. into the group before 28 days to accept other anticancer treatment;
• •14. other information: dysfunction of blood coagulation (INR\>1.5 or prothrombin time ( PT )\> ULN+4 Seconds); Anticoagulant therapy are receiving antithrombotic or infection who needed intravenous antibiotics; previously receiving bevacizumab treatment or other anti- VEGF TKI Drug treatment, with a second tumor (except basal cell carcinoma and cervical carcinoma in situ);
• •15. a history of immunodeficiency, including HIV testing positive, or suffer from other acquired, congenital immune deficiency disease or have a history of organ transplantation;